GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amryt Pharma PLC (NAS:AMYT) » Definitions » Net Interest Income (for Banks)

Amryt Pharma (Amryt Pharma) Net Interest Income (for Banks)


View and export this data going back to 2019. Start your Free Trial

What is Amryt Pharma Net Interest Income (for Banks)?

Net Interest Income only applies to banks.


Amryt Pharma (Amryt Pharma) Business Description

Industry
Traded in Other Exchanges
N/A
Address
196 High Road, Dept 920A, Wood Green, London, GBR, N22 8HH
Amryt Pharma PLC is a specialty pharmaceutical company. It is focused on developing and delivering new treatments to help improve the lives of patients with rare or orphan diseases. It holds an exclusive license to sell Lojuxta (lomitapide) for adults, across the European Union and other territories including the Middle East, North Africa, Turkey and Israel. Lojuxta is used to treat a rare life-threatening disease called Homozygous Familial Hypercholesterolemia. Myalept (metreleptin) is an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients. It derives most of the revenue from the European Economic Area (EEA).